Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

c-erbB-2 protein expression in node negative breast cancer.

J Richner1, H A Gerber, G W Locher

  • 1Ludwig Institute for Cancer Research, Bern Branch, Switzerland.

Annals of Oncology : Official Journal of the European Society for Medical Oncology
|July 1, 1990
PubMed
Summary

This study found that c-erbB-2 protein expression alone does not predict breast cancer survival. However, combining c-erbB-2 status with estrogen receptor status may offer prognostic value.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Final outcomes of the SOFT and TEXT phase III trials in premenopausal hormone receptor-positive early breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

Genomic characterisation of hormone receptor-positive breast cancer arising in very young women.

Annals of oncology : official journal of the European Society for Medical Oncology·2023
Same author

Moderate penetrance genes complicate genetic testing for breast cancer diagnosis: ATM, CHEK2, BARD1 and RAD51D.

Breast (Edinburgh, Scotland)·2022
Same author

Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy.

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same author

Reply to Does the expert panel at the St Gallen meeting provide an unbiased opinion about the management of women with early breast cancer?

Annals of oncology : official journal of the European Society for Medical Oncology·2020
Same author

International consensus on treatment of early breast cancer: radiotherapy issues A response to 'International expert consensus on radiotherapy of early breast cancer'.

Annals of oncology : official journal of the European Society for Medical Oncology·2020

Area of Science:

  • Oncology
  • Molecular Biology
  • Biomarker Research

Background:

  • c-erbB-2 protein is a marker implicated in various cancers.
  • Its prognostic significance in breast cancer, particularly in relation to other biomarkers, requires further clarification.

Purpose of the Study:

  • To investigate the prognostic value of c-erbB-2 protein expression in breast cancer patients.
  • To determine if c-erbB-2 expression correlates with disease-free survival (DFS) and overall survival (OS).
  • To assess the combined prognostic utility of c-erbB-2 and estrogen receptor (ER) status.

Main Methods:

  • Comparative analysis of c-erbB-2 protein expression in paraffin-embedded tumor sections from breast cancer patients with and without relapse.
  • Immunohistochemical staining using a polyclonal antibody against c-erbB-2 protein.

Related Experiment Videos

  • Statistical analysis of DFS and OS in relation to c-erbB-2 expression and ER status.

    • Main Results:

    • c-erbB-2 staining was observed in a subset of patients in both relapse-free and relapse groups.
    • No significant correlation was found between the extent of c-erbB-2 expression and DFS or OS as independent factors.
    • Patients with ER-positive primaries and negative c-erbB-2 expression exhibited the longest DFS and OS.

    Conclusions:

    • c-erbB-2 protein expression alone is not a reliable independent predictor of breast cancer outcomes.
    • The combination of ER status and c-erbB-2 expression provides a more informative prognostic assessment.
    • Clinical utility of c-erbB-2 in breast cancer management necessitates consideration of other prognostic variables like ER status.